An emotional bond with patients is key, says Elemental Machines' Iyengar

An emotional bond with patients is key, says Elemental Machines' Iyengar

At the MM&M Transforming Healthcare conference, Iyengar told attendees how to take into account a consumer's behavior and emotion when marketing medical products.

Care Angel wins MM&M Shark Tank challenge 2016

The Siri for Seniors took the top prize at the second MM&M Shark Tank for its annual healthcare conference.

Omnicom to acquire BioPharm Communications

Omnicom to acquire BioPharm Communications

Omnicom recently reorganized its health agencies under the Omnicom Health Group umbrella.

Five things for pharma marketers to know: Thursday, May 5, 2016

Five things for pharma marketers to know: Thursday, May 5, 2016

U.S. Keytruda sales miss mark; the CDC warns parents to try therapy before drugs for children with ADHD; FDA panel recommends training for opioid prescribers

Time is running out: Fill in MM&M's Agency questionnaire

Time is running out: Fill in MM&M's Agency questionnaire

Did your agency report record growth in 2015? Tell us why when you fill out the A-to-Z questionnaire for MM&M's upcoming agency issue. The deadline is Friday.

Five things for pharma marketers to know: Wednesday, May 4, 2016

Five things for pharma marketers to know: Wednesday, May 4, 2016

The FDA issues warning for certain antipsychotics; Shkreli may face more securities charges; Genentech and Stand Up to Cancer launch campaign

Five things for pharma marketers to know: Tuesday, May 3, 2016

Five things for pharma marketers to know: Tuesday, May 3, 2016

IMS and Quintiles to merge and create $17 billion firm; Biogen spins off hemophilia company; Google partners with the National Health Service

2016 Pharma Report: All the data in one place

2016 Pharma Report: All the data in one place

Learn more about the top therapeutic categories by sales, top companies by revenue, top drugs by sales, and more.

Bristol-Myers Squibb plans to spend more on DTC for Opdivo

Bristol-Myers Squibb plans to spend more on DTC for Opdivo

The drugmaker said it plans to increase its investment in DTC for the immuno-oncology drug.

Five things for pharma marketers to know: Thursday, April 28, 2016

Five things for pharma marketers to know: Thursday, April 28, 2016

Pfizer settles rebate suit; Sanofi moves to acquire Medivation; AstraZeneca sells US rights to gout drug

Senate committee condemns Valeant's business model

Senate committee condemns Valeant's business model

The Senate committee on Aging said Valeant's missteps go beyond price hikes and that its business model is fundamentally to blame.

MM&M's Hall of Femme: 20 women to watch

MM&M's Hall of Femme: 20 women to watch

The MM&M Women to Watch, part of our inaugural Hall of Femme, salutes 20 aspiring healthcare commercial and marketing execs distinguishing themselves.

MM&M's Hall of Femme: 16 women leaders who changed the industry

MM&M's Hall of Femme: 16 women leaders who changed the industry

The 16 women profiled here number among those who have bridged the gender gap in agencies, biopharma, and medtech.

Publicis Healthcare names Jarecke-Cheng global comms chief

Publicis Healthcare names Jarecke-Cheng global comms chief

Publicis Healthcare Communications Group has hired Kipp Jarecke-Cheng as global chief communications officer.

Five things for pharma marketers to know: Wednesday, April 27, 2016

Five things for pharma marketers to know: Wednesday, April 27, 2016

Pearson expected to say price hikes were too aggressive; Collegium's painkiller receives full FDA approval; most hospitals stop advertising infant formula

Infographic: the growing biosimilar market in the U.S.

Infographic: the growing biosimilar market in the U.S.

The FDA has approved two biosimilars, but questions remain about how quickly providers and patients in the U.S. will adopt them.

Following positive outcomes data, a new diabetes class is on the rise

Following positive outcomes data, a new diabetes class is on the rise

Eli Lilly noted in its first-quarter earnings report that SGLT2 inhibitors, a treatment for type 2 diabetes patients, are surging.

Five things for pharma marketers to know: Tuesday, April 26, 2016

Five things for pharma marketers to know: Tuesday, April 26, 2016

FDA panel says Duchenne drug is not effective; Bill Ackman to appear before Senate committee investigating pricing issues; Daiichi Sankyo to open new headquarters

About.com launches first standalone health site Verywell

About.com launches first standalone health site Verywell

Verywell.com presents physician-reviewed health and wellness content that aims to be "gentler" than other health websites.

Biogen under investigation for patient-assistance programs

Biogen under investigation for patient-assistance programs

The drugmaker disclosed in its first-quarter earnings report that it is being investigated over ties to nonprofit foundations.

FCB agency veteran, Renée Wills, joins Kinch

FCB agency veteran, Renée Wills, joins Kinch

After six years as president of Trio, Renée Wills has joined newly formed agency Kinch.

Five things for pharma marketers to know: Monday, April 25, 2016

Five things for pharma marketers to know: Monday, April 25, 2016

Valeant names new CEO; Novartis weighs sales of stake in Roche; FDA ad panel to recommend DMD drug

Be a better mentor, says Baxalta's Leonardi

Be a better mentor, says Baxalta's Leonardi

Too often left undiscussed is that a powerful business case can be made for more frequent and focused mentorship.

Novartis launches DTC campaign for Entresto

Novartis launches DTC campaign for Entresto

The loss of patent exclusivity for cancer drug Gleevec contributed to a 12% sales drop, but the drugmaker expects sales from Entresto and Cosentyx to pick up the slack.

Five things for pharma marketers to know: Friday, April 22, 2016

Five things for pharma marketers to know: Friday, April 22, 2016

AstraZeneca to sequence two million genomes; Valeant considering Perrigo CEO as its new chief executive; AMA and PhRMA each spent $6 million on lobbying

Biogen turned to DTC to address 'low awareness' of MS drug

Biogen turned to DTC to address 'low awareness' of MS drug

Biogen CEO George Scangos told investors that the company's DTC campaign for Tecfidera was designed to address low awareness for the drug.

Five things for pharma marketers to know: Thursday, April 21, 2016

Five things for pharma marketers to know: Thursday, April 21, 2016

Allergan plans sales blitz for Kybella; Novartis U.S. lead steps down; analysts say PCSK9 sales are disappointing so far

An explainer: some of IBM Watson Health's key partnerships

An explainer: some of IBM Watson Health's key partnerships

IBM Watson Health has publicly announced deals with 18 different companies and patient organizations over the past few years.

Brazilian agencies create billboard that kills Zika-carrying mosquitoes

Brazilian agencies create billboard that kills Zika-carrying mosquitoes

The billboards themselves operate on simple principles: fool mosquitoes into thinking they've found a human, and then trap them until they die of dehydration.

Five things for pharma marketers to know: Wednesday, April 20, 2016

Five things for pharma marketers to know: Wednesday, April 20, 2016

Immuno-oncology drugs showing results in hard-to-treat cancers; Express Scripts responds to Anthem lawsuit; BI and Lilly plan outcomes trials for Jardiance

Watson Health partners with drug and devicemakers to tap into real-world data

Watson Health partners with drug and devicemakers to tap into real-world data

Industry is partnering with Watson to try and solve some of healthcare's most pressing questions.

Competition drives down sales of J&J's Olysio

Competition drives down sales of J&J's Olysio

The company said growth in its immunology portfolio offset declining Olysio sales.

Five things for pharma marketers to know: Tuesday, April 19, 2016

Five things for pharma marketers to know: Tuesday, April 19, 2016

Novartis CEO under pressure to restore investor confidence; Orexigen terminates obesity drug; startup invests in shaky cholesterol-drug class

Intouch Solutions' Weissberg on the rising payer voice

Intouch Solutions' Weissberg on the rising payer voice

The group director of Intouch Solutions' newly launched market access business is betting that the payer will gain in influence.

Is virtual reality the ultimate emotive storytelling tool?

Is virtual reality the ultimate emotive storytelling tool?

Wieden+Kennedy Portland's VR work for the National Multiple Sclerosis Society lets wheelchair-bound patients experience their favorite activities again, like dancing or surfing.

How Watson for Oncology is advancing cancer care

How Watson for Oncology is advancing cancer care

IBM Watson Health's cognitive computing system for oncology tackles one of the leading causes of death worldwide and attempts to eradicate misdiagnoses.

Bayer creates new role: VP of comms for consumer health

Bayer creates new role: VP of comms for consumer health

He plans to expand the company's consumer health marketing.

Five things for pharma marketers to know: Monday, April 18, 2016

Five things for pharma marketers to know: Monday, April 18, 2016

Valeant mulls over fire sale; research shows that Opdivo helps advanced melanoma patients survive longer; AstraZeneca considers Medivation

Challenges exist, even as excitement grows for big data market

Challenges exist, even as excitement grows for big data market

The move away from a fee-for-service reimbursement model and the arrival of promising new technology have created demand for big data in healthcare.

What is cognitive computing, and what does it look like in healthcare?

What is cognitive computing, and what does it look like in healthcare?

Already, there's cognitive cooking for your kitchen and cognitive coaching for your daily run. What's Watson's vision for medicine?

Using humor: Why pharma doesn't need to fear social media

Using humor: Why pharma doesn't need to fear social media

Healthcare and tech executives say it's possible for pharma to engage, use humor, and have fun on social media.

A look at Watson Health in New York

A look at Watson Health in New York

The editorial staff of MM&M recently visited IBM Watson's offices in New York. What ensued was the creation of Watson Week.

Five things for pharma marketers to know: Friday, April 15, 2016

Five things for pharma marketers to know: Friday, April 15, 2016

Bristol-Myers Squibb seeks new indication for Opdivo; Clinton received $2.8 million from the healthcare industry; Quest creates tests for hep.-C drugs

MM&M's Agency questionnaire is now available

MM&M's Agency questionnaire is now available

The questionnaire gives agencies the opportunity to contribute information to MM&M's definitive Agency A-to-Z directory, which will be published in the July issue.

Five things for pharma marketers to know: Thursday, April 14, 2016

Five things for pharma marketers to know: Thursday, April 14, 2016

Government identifies barriers to eliminating hepatitis C; Pearson agrees to congressional deposition; CMS reportedly plans to revoke Theranos license

Second-generation IBM star pushes for partnerships

Second-generation IBM star pushes for partnerships

With a lead role in IBM Watson's bold gambit to transform healthcare, Kathy McGroddy-Goetz ranks as one of the enterprise's most important individuals.

U.S. drug spend jumped 12% in 2015

U.S. drug spend jumped 12% in 2015

2015 marks the second straight double digit increase in spend, which was driven by recent launches and specialty brands.

Five things for pharma marketers to know: Wednesday, April 13, 2016

Five things for pharma marketers to know: Wednesday, April 13, 2016

Sanofi is reportedly interested in buying Medivation; Sean Parker funds $250 million cancer research institute; FDA will review Merck's allergy biologic

Creative partners should push pharma clients to tell better stories

Creative partners should push pharma clients to tell better stories

Industry criticism can create opportunities for drugmakers and other healthcare organizations to create a stronger narrative.

FDA committee votes no on Clovis lung-cancer drug

FDA committee votes no on Clovis lung-cancer drug

The FDA advisory committee voted 12-1 against approving the therapy, citing safety issues and requesting more data.

Five things for pharma marketers to know: Tuesday, April 12, 2016

Five things for pharma marketers to know: Tuesday, April 12, 2016

California bill would require price disclosures; AbbVie's and Genentech's blood-cancer drug is approved; FDA expands metformin use

The FDA approves AbbVie's and Roche's blood cancer drug

The FDA approves AbbVie's and Roche's blood cancer drug

Analysts have estimated the drug could reach $2 billion in sales in the next four years.

At Work With: Cello Health's Jon Bircher

At Work With: Cello Health's Jon Bircher

"I continue to look for ways to stretch myself or ways I can get involved or influence the business," said the new CCO of Cello Health.

Five things for pharma marketers to know: Monday, April 11, 2016

Five things for pharma marketers to know: Monday, April 11, 2016

Valeant's missteps derailed Addyi; Biogen reportedly considers selling its hemophilia treatment portfolio; Roche's PD-LI inhibitor granted Priority Review

Which brands spent the most on professional ads in 2015?

Which brands spent the most on professional ads in 2015?

Here are the brands and companies that advertised the most on professional ads in 2015.

When it comes to professional ads, print makes its comeback

When it comes to professional ads, print makes its comeback

Following print's best year since 2011, it's time to rewrite those journal-advertising obituaries. Medical-surgical print journal spending in 2015 was up 8.4% to $372 million.

What 10 innovation teams look like

What 10 innovation teams look like

Learn about Merck's new innovation team as well as read profiles of 9 other teams at companies such as Google and Johnson & Johnson.

Five things for pharma marketers to know: Friday, April 8, 2016

Five things for pharma marketers to know: Friday, April 8, 2016

Analyst survey says docs want outcomes benefit from PCSK9s; Allergan licenses early-stage Alzheimer's drugs; Pfizer and IBM partner in Parkinson's disease

Five things for pharma marketers to know: Thursday, April 7, 2016

Five things for pharma marketers to know: Thursday, April 7, 2016

Pfizer considers its options, post-Allergan deal; Allergan CEO says Treasury's rule-change was 'un-American;' IBM partners with Pfizer to study Parkinson's

Omnicom merges Corbett, LLNS into TBWA/ WorldHealth brand

Omnicom merges Corbett, LLNS into TBWA/ WorldHealth brand

LLNS CEO Sharon Callahan has been named CEO of TBWA/WorldHealth, which is based in New York.

Infographic: Better promotion of clinical trials

Infographic: Better promotion of clinical trials

Companies spend $2 billion per year recruiting patients for clinical trials. A survey of 702 adults, conducted from December 2015 to January 2016, points to a need for more awareness.

InVentiv Health files for IPO

InVentiv Health files for IPO

It operates a number of ad agencies, like GSW and Palio, as well as a group of PR firms that includes Chandler Chicco Agency.

Drugmakers go to DTC to promote IBS drugs

Drugmakers go to DTC to promote IBS drugs

The launch this week of the first DTC campaign for Viberzi follows a wave of direct-to-consumer campaigns focused on promoting treatments for the two types of IBS.

MannKind reworks commercial strategy for Afrezza

MannKind reworks commercial strategy for Afrezza

After buying back the rights to the therapy, the biopharmaceutical company is building a endocrinology sales force and hiring a new advertising agency.

Five things for pharma marketers to know: Wednesday, April 6, 2016

Five things for pharma marketers to know: Wednesday, April 6, 2016

Pfizer and Allergan call off merger; the FDA approves second biosimilar; NEJM comes under fire

Retaining talent: How pharma can compete with Google

Retaining talent: How pharma can compete with Google

As tech behemoths like Google are attempting to poach the best and brightest, executives from pharma companies and agencies share new retention tactics.

New mobile app seeks to address medication adherence

New mobile app seeks to address medication adherence

CeyHello, a newly launched social networking mobile app, tackles medication adherence by connecting patients, caregivers and family members.

Amgen takes issue with yet-to-be published multiple-myeloma drug report

Amgen takes issue with yet-to-be published multiple-myeloma drug report

The drugmaker instead suggested using an economic model it developed.

Five things for pharma marketers to know: Tuesday, April 5, 2016

Five things for pharma marketers to know: Tuesday, April 5, 2016

Valeant terminates Addyi's sales force; the Treasury Department issues new tax-inversion rules; MannKind buys back its marketing rights to Afrezza

Eli Lilly's failed trial could spell the end for CETP inhibitors

Eli Lilly's failed trial could spell the end for CETP inhibitors

The results of a failed trial for Lilly's CEPT inhibitor has analysts saying there is little hope for Merck's drug in the same class.

Five things for pharma marketers to know: Monday, April 4, 2016

Five things for pharma marketers to know: Monday, April 4, 2016

Four best-selling drugs in the U.S. had their prices increase by 100% since 2011; Gilead acquires NASH asset; Lilly's unveils CETP inhibitor data

The FDA issues warning letter to Shionogi over co-pay voucher

The FDA issues warning letter to Shionogi over co-pay voucher

The drugmaker marketed a co-pay assistance voucher that failed to provide any risk information about its drug Ulesfia.

2015 DTC spending: All the data in one place

2015 DTC spending: All the data in one place

Drugmakers spent 20% more on DTC ads in 2015 than in 2014. Eli Lilly was the top spender, shelling out $220.4 million to promote Cialis, its erectile dysfunction drug.

A ranking of 2015's DTC Ads

A ranking of 2015's DTC Ads

Great DTC pharma advertising during the last year or so has been "sparse," says SSCG Media Group president Debbie Renner. Still, here are her top 10 picks for 2015.

DTC Report 2016: Gut Check

DTC Report 2016: Gut Check

DTC is facing a new test from physicians and politicians. Here's why critics fear a deluge, and how they're pushing back.

Five things for pharma marketers to know: Friday, April 1, 2016

Five things for pharma marketers to know: Friday, April 1, 2016

GSK won't patent drugs sold in low-income countries; experimental dermatitis therapy met Phase III endpoints; the FDA issues biosimilar labeling guidance

How to win an MM&M award: the do's and the don'ts

How to win an MM&M award: the do's and the don'ts

Tip: Don't charge your intern with assembling your entry. Read more from our checklists of do's and don'ts, and don't forget that entries are due April 11.

Healthcare industry seeks to reform its position as hacking target

Healthcare industry seeks to reform its position as hacking target

Given the value of its data and its relatively backward security measures, the healthcare industry has become a prime target for hackers. But industry experts say changes are afoot.

Five things for pharma marketers to know: Thursday, March 31, 2016

Five things for pharma marketers to know: Thursday, March 31, 2016

The FTC asks for more info about Pfizer-Allergan deal; the FDA loosens guidelines for abortion-inducing drug; startup to deliver Truvada through an app

Another physician group raises concerns about DTC

Another physician group raises concerns about DTC

The American College of Physicians questioned the role direct-to-consumer advertising plays in contributing to prescription drug costs.

Five things for pharma marketers to know: Wednesday, March 30, 2016

Five things for pharma marketers to know: Wednesday, March 30, 2016

There are 23 biosimilars ready to file with the FDA; an FDA committee votes in favor of Parkinson's disease drug; Bloomberg funds new immunotherapy center

LehmanMillet becomes Precisioneffect following acquisition

LehmanMillet becomes Precisioneffect following acquisition

The Boston-based agency was acquired by Precision Medicine Group in May.

Levy joins PatientsLikeMe, bringing the analyst closer to the patient in latest career move

Levy joins PatientsLikeMe, bringing the analyst closer to the patient in latest career move

Monique Levy, who's spent more than a decade helping drugmakers understand technology shifts, has joined PatientsLikeMe, the online discussion platform for people with chronic illness.

W2O, Lagrant Foundation team up on healthcare diversity push

W2O, Lagrant Foundation team up on healthcare diversity push

The healthcare-focused agency network is committed to spending $50,000 over three years to the Future Leaders in Healthcare Fellowship Program.

WPP acquires CMI, retains minority stake in Compas

WPP acquires CMI, retains minority stake in Compas

WPP's acquisition of CMI, a significant player in the healthcare media-planning space, will likely bolster the services it provides to pharma clients.

Ascension Health rolls out first ad campaign for VA

Ascension Health rolls out first ad campaign for VA

The Catholic health system worked with FleishmanHillard and GSD&M to create the integrated campaign touting its partnership with the Department of Veterans Affairs.

Five things for pharma marketers to know: Tuesday, March 29, 2016

Five things for pharma marketers to know: Tuesday, March 29, 2016

Lawmakers call out high price of Xtandi; Novo Nordisk breaks ground in North Carolina; Sanofi poaches top research scientist from AstraZeneca

Devicemakers eye market for drug adherence

Devicemakers eye market for drug adherence

Insulet's skin-adhesive technology is being used to improve adherence for patients taking biologics.

Five things for pharma marketers to know: Monday, March 28, 2016

Five things for pharma marketers to know: Monday, March 28, 2016

Experts say DTC spending is a waste; Alder BioPharma's migraine drug meets study goal; sources tell Stat that execs are leaving Verily Life Sciences

Teva targets opioid abuse with the absurd

Teva targets opioid abuse with the absurd

The drugmaker launched a three-part video series that uses humor to address prescription drug abuse.

Drugmakers move to counteract expiring patents with new respiratory drugs

Drugmakers move to counteract expiring patents with new respiratory drugs

Symptom-driven care is falling out of fa­vor with lung-drug leaders increasingly interested in assigning optimal treatment approaches to patient conditions.

Corbus bets on cystic-fibrosis market with Resunab

Corbus bets on cystic-fibrosis market with Resunab

Current treatments, including steroids and ibuprofen, help control symptoms. But the side-effect profiles are difficult for patients to manage.

Top 25 respiratory products, 2014-2015

Top 25 respiratory products, 2014-2015

GlaxoSmithKline's Advair brought in $4.8 billion in U.S. sales in 2015, edging out Boehringer Ingelheim's Spiriva Handihaler ($3.4 billion) and AstraZeneca's Symbicort ($2.6 billion).

Giant hires new Philadelphia GM and creative director

Giant hires new Philadelphia GM and creative director

Giant appointed Ben Mallory, who has held creative leadership roles at AstraZeneca, as its new executive creative director.

Sudler & Hennessey acquires West Coast digital marketing firm

Sudler & Hennessey acquires West Coast digital marketing firm

Viscira, a digital marketing agency, works with GlaxoSmithKline, Merck, and Genentech, among other life-sciences companies.

Five things for pharma marketers to know: Friday, March 25, 2016

Five things for pharma marketers to know: Friday, March 25, 2016

Gilead to pay Merck $200 million in HCV patent infringement suit; some patients aren't prescribed blood thinners; the FDA issues generic opioid guidance

Five things for pharma marketers to know: Thursday, March 24, 2016

Five things for pharma marketers to know: Thursday, March 24, 2016

Valeant hiked price of assisted-suicide drug; Bristol-Myers Squibb acquires autoimmune drugmaker; the FDA approves Teva's asthma drug

Facebook's Everson: Agencies lagging on mobile creative

Facebook's Everson: Agencies lagging on mobile creative

Facebook has found that 43% of people who watch the first three seconds of a video will stay for 10 seconds. To create engagement, agencies need to rethink the creative approach.

Politics led to DTC uproar, but curbs unlikely in current climate

Politics led to DTC uproar, but curbs unlikely in current climate

Anti-DTC measures are unlikely to be enacted even though the backlash itself is a function of political change.

Precision for Medicine acquires ACT Oncology

Precision for Medicine acquires ACT Oncology

The scientific services company expands its portfolio to include expertise in oncology clinical studies.

OPINION


Click here to learn about the Agency Issue. 

Email Newsletters